Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity ARGENICA THERAPEUTICS LIMITED ABN/ARBN Financial year ended: 78 637 578 753 30 JUNE 2026 ...
Appendix 4G & Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Notification of cessation of securities - AGN
- ARG007 Shows Significant Neuroprotection in Concussion Study
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- WHO Confirms Xaranetide as INN for ARG-007
- IND Application Advanced With Successful Completion of Assay
Later from Argenica Therapeutics
- Appendix 4E & Annual Report to 30 June 2026
- Concussion Data Selected for Neurotrauma Congress
- AGM Date & Closing Date for Director Nominations
- Change of Director's Interest Notice
- Notice of Annual General Meeting/Proxy Form
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics